Beyond PD-L1: Unraveling the enigma of immunotherapy response in PD-L1 negative (<1%) NSCLC patients through quantification of PD-1/PD-L1 engagement in the tumor microenvironment

被引：0

作者：

Gumuzio, Juan

Calleja, Veronique

Miles, James

Sancehz-Magraner, Lissete

Aguirre, Fernando

机构：

来源：

MOLECULAR CANCER THERAPEUTICS | 2023年 / 22卷 / 12期

关键词：

D O I：

10.1158/1535-7163.TARG-23-A124

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

A124

引用

页数：2

共 50 条

[21] PD-1, PD-L1, PD-L2 expression in the chordoma microenvironment
Dimitrios Mathios
Jacob Ruzevick
Christopher M. Jackson
Haiying Xu
Sagar Shah
Janis M. Taube
Peter C. Burger
Edward F. McCarthy
Alfredo Quinones-Hinojosa
Drew M. Pardoll
Michael Lim
Journal of Neuro-Oncology, 2015, 121 : 251 - 259
[22] Adipose PD-L1 Modulates PD-1/PD-L1 Checkpoint Blockade Immunotherapy Efficacy in Breast Cancer
Wu, Bogang
Sun, Xiujie
Gupta, Harshita B.
Yuan, Bin
Li, Jingwei
Ge, Fei
Chiang, Huai-Chin
Zhang, Xiaowen
Zhang, Chi
Zhang, Deyi
Yang, Jing
Hu, Yanfen
Curiel, Tyler J.
Li, Rong
ONCOIMMUNOLOGY, 2018, 7 (11):
[23] Biomarkers of response to PD-1/PD-L1 inhibition
Vareki, Saman Maleki
Garrigos, Carmen
Duran, Ignacio
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2017, 116 : 116 - 124
[24] Determination of PD-L1 positive CETCs as a biomarker for PD-1/PD-L1 treatment monitoring
Pizon, M.
Schott, D.
Pachmann, U.
Pachmann, K.
ONCOLOGY RESEARCH AND TREATMENT, 2017, 40 : 89 - 89
[25] Highly Activated PD-1/PD-L1 Pathway in Gastric Cancer with PD-L1 Expression
Saito, Hiroaki
Kono, Yusuke
Murakami, Yuki
Shishido, Yuji
Kuroda, Hirohiko
Matsunaga, Tomoyuki
Fukumoto, Yoji
Osaki, Tomohiro
Ashida, Keigo
Fujiwara, Yoshiyuki
ANTICANCER RESEARCH, 2018, 38 (01) : 107 - 112
[26] Measurement of soluble PD-1 and soluble PD-L1 as well as PD-L1 and PD-1 from perioperative patients with gastric carcinoma
Wei, Hangzhi
Wu, Fahong
Mao, Yudong
Zhang, Youcheng
Leng, Guangxian
Wang, Jia
Zhang, Wei
Wang, Tianwei
JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2022, 52 (04) : 331 - 345
[27] Intracellular Signaling triggered by engagement of PD-1 by PD-L1
Bu, Xia
Bu, Melissa
Hua, Ping
Zhu, Baogong
Sharpe, Arlene H.
Freeman, Gordon J.
JOURNAL OF IMMUNOLOGY, 2020, 204 (01):
[28] PD-1 and PD-L1 prognostic in UTUC
Louise Stone
Nature Reviews Urology, 2017, 14 : 518 - 518
[29] A snapshot of the PD-1/PD-L1 pathway
Ghosh, Chinmoy
Luong, Gary
Sun, Yue
JOURNAL OF CANCER, 2021, 12 (09): : 2735 - 2746
[30] Cancer immunotherapy and the PD-1/PD-L1 checkpoint pathway
Barclay, Jonathan
Creswell, Joanne
Leon, Juan
ARCHIVOS ESPANOLES DE UROLOGIA, 2018, 71 (04): : 393 - 399

← 1 2 3 4 5 →

Beyond PD-L1: Unraveling the enigma of immunotherapy response in PD-L1 negative (&lt;1%) NSCLC patients through quantification of PD-1/PD-L1 engagement in the tumor microenvironment

Beyond PD-L1: Unraveling the enigma of immunotherapy response in PD-L1 negative (<1%) NSCLC patients through quantification of PD-1/PD-L1 engagement in the tumor microenvironment